non-hormonal, non-invasive treatment intended to work across different genders, skin types, and hair types. The company is currently conducting Phase 2a clinical trials in androgenetic alopecia and aims to expand into other hair loss conditions. Its scientific team draws on work in stem cell biology and metabolic regulation and publishes its translational and clinical data in peer-reviewed channels.